Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021)

Capricor Therapeutics' (CAPR) quarterly Notes Payables came in at $282691.0 in Q1 2021, up 14.59% quarter-over-quarter from $246689.0 in Q4 2020.

Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021) Analysis & Trends

Capricor Therapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $282691.0 for Q1 2021.

On a quarterly basis, Notes Payables changed N/A year-over-year to $282691.0 in Q1 2021; TTM through Mar 2021 was $282691.0, a N/A change from a year earlier, with the FY2020 full-year figure at $246689.0, changed N/A from the prior year.
Notes Payables rose to $282691.0 in Q1 2021 per CAPR's latest filing, from $246689.0 in the prior quarter.
Across five years, Notes Payables topped out at $282691.0 in Q1 2021 and bottomed at $139927.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Capricor Therapeutics	1.12 Bn	1.12 Bn	-

Download Data